Tafamidis

• Background :

  A potent and selective transthyretin (TTR) kinetic stabilizer. It binds selectively and with negative cooperativity to the two normally unoccupied thyroxine binding sites of the TTR tetramer (Kd = ~2 and ~200 nM) 1. Stabilizes wild-type and mutant TTR under varying conditions in vitro (EC50=2.7-3.2 M) .1 Clinically useful for the treatment of familial amyloid polyneuropathy2,3 and TTR-related cardiomyopathy4.

• Conjugation :

  Unconjugated

• Buffer :

  Off-white solid

• Storage Conditions :

  -20°C